Newsletters

HHS formally re-established ACIP’s charter after withdrawing an April revision, leaving questions about whether the agency may still seek to reshape the committee ahead of the June meeting, which is still listed on CDC’s website despite a court order temporarily barring the committee from convening; FDA leadership turnover continued across the agency’s drug and vaccine centers, adding uncertainty around regulatory decision-making and vaccine oversight.

FDA Commissioner Makary has resigned, marking the latest in a series of leadership disruptions across HHS agencies; A new systematic review found no evidence linking aluminum in vaccines to autism or other chronic health conditions, adding to a significant body of evidence.

HHS leadership continues to evolve: Trump nominated Nicole Saphier for Surgeon General, and the FDA named Katherine Szarama as Acting Director of CBER (the agency’s vaccine center), replacing Vinay Prasad; the DOJ appealed a preliminary injunction that blocked several of Kennedy’s vaccine policy changes as AAP’s lawsuit against HHS proceeds, though the government did not provide a rationale for the appeal.

The Trump Administration has moved to pause the vaccine policy lawsuit brought by leading medical organizations, while reverting the CDC’s website to prior immunization schedules, leaving federal vaccine guidance in a holding pattern; lawmakers from both parties pressed HHS Secretary Robert F. Kennedy Jr. on vaccine policy during a series of congressional hearings last week, questioning him on shifting measles messaging and raising concerns about public health communication.

President Trump has nominated Dr. Erica Schwartz to lead the CDC, signaling a potential shift toward more traditional public health leadership amid ongoing instability; Trump also announced appointments for three other CDC leadership roles; during his testimony before three key committees last week, HHS Secretary Kennedy faced scrutiny from members of Congress over vaccine policy and measles; Kennedy is appearing before four more committees this week.

HHS published an updated ACIP charter, expanding the committee’s role and signaling a shift in how immunization recommendations could be made in the future; CDC delayed publication of a report on Covid vaccine effectiveness, while an ICER analysis of Covid vaccine effectiveness and value reinforced individual net health benefits.

HHS has moved to renew ACIP’s charter—a move that could open the door to reconstitution of the advisory panel and ultimately impact future vaccine recommendations; Pfizer and BioNTech have paused a large U.S. Covid vaccine trial due to low enrollment, reflecting broader shifts in vaccine demand, policy, and research investment 

The White House has delayed nominating a CDC Director, leaving current leadership in place with limited authority under federal rules; new proposals and legal pressures could expand how vaccine-related injuries are tracked and compensated through federal programs, raising concerns about advancing changes without clear scientific consensus.

The FDA’s top infectious disease regulator is leaving the agency in April along with other senior agency staff; HHS is working to identify the next CDC Director, who must be nominated by this Thursday to allow Dr. Jay Bhattacharya to continue serving as Acting Director.

A federal judge stayed government changes to federal vaccine policy—including the reconstitution of ACIP membership, all votes taken by the new Committee, and the CDC’s January revision of the childhood immunization schedule—while a lawsuit against HHS proceeds; the ruling resulted in the postponement of this week’s scheduled ACIP meeting, which was set to focus on Covid vaccines and vaccine injury as well as a number of topics outside of the Committee’s remit.